Generic Launches Continue at Mylan - Analyst Blog

By
A A A

Mylan Pharmaceuticals Inc., a subsidiary of generic player, Mylan Inc. ( MYL ), recently announced that it has received final approval from the U.S. Food & Drug Administration (FDA) to launch generic versions of Plavix (clopidogrel), 75 mg and 300 mg. Mylan was the first company to have filed an abbreviated new drug application (ANDA) to market a generic version of Plavix, 300 mg. The early bird will thus enjoy a 180-day period of exclusivity.

Plavix, sold by Bristol-Myers Squibb Co. ( BMY ) and Sanofi ( SNY ), is approved for patients who have had a heart attack or stroke recently, or suffer from a partial or total blockage of an artery (peripheral artery disease). According to IMS Health, Plavix generated U.S. revenues of approximately $6.7 billion for the 12 months ending March 31, 2012.

Apart from Mylan, Apotex Corporation, Aurobindo Pharma, Roxane Laboratories, Sun Pharma, Teva Pharmaceuticals ( TEVA ) and Torrent Pharmaceuticals gained approval for the 75 mg dosage of clopidogrel. Meanwhile, Dr. Reddy's Laboratories ( RDY ), Gate Pharmaceuticals and Teva have received FDA approval for the 300 mg dosage of clopidogrel. Dr. Reddy's was also among the first companies to file an ANDA for generic Plavix 300 mg and has 180 days of marketing exclusivity for the formulation.


As of May 17, 2012, the company had 173 ANDAs pending clearance by the FDA, targeting $98.2 billion in branded sales. Mylan believes that about 39 of these ANDAs are first-to-file opportunities, representing approximately $25.5 billion in branded sales. The revenue figures are as per IMS health for the 12 months ending December 31, 2011.            

Our Recommendation

We are encouraged by Mylan's geographic reach and product depth along with a robust generic product pipeline. However, we are concerned about the company's lackluster performance in Europe, the Middle East and Africa (EMEA) region. Additionally, with most large branded drugs due to lose patent exclusivity within 2017-2018, we have little visibility on the growth prospects for generic companies like Mylan beyond that timeframe.

Thus, we prefer to remain on the sidelines and have a Neutral recommendation on Mylan. The stock carries a Zacks #3 Rank ("Hold" rating) in the short term.


 
BRISTOL-MYERS (BMY): Free Stock Analysis Report
 
MYLAN INC (MYL): Free Stock Analysis Report
 
DOCTOR REDDYS (RDY): Free Stock Analysis Report
 
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
 
TEVA PHARM ADR (TEVA): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ANDA , BMY , MYL , RDY , SNY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

33,974,386
  • $17.98 ▲ 0.28%
20,763,901
  • $91.29 ▲ 2.06%
19,110,793
  • $7.26 ▼ 1.22%
18,528,869
    $8.33 unch
18,014,920
  • $4.19 ▼ 1.18%
16,448,919
  • $25.83 ▼ 0.19%
14,748,190
  • $7.60 ▼ 1.43%
14,144,383
  • $112.01 ▼ 0.47%
As of 12/24/2014, 02:12 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com